Actively Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Led by CellCentric Ltd. · Updated on 2025-12-18
250
Participants Needed
39
Research Sites
398 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
CONDITIONS
Official Title
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided consent to participate
- ECOG performance status between 0 and 2
- Diagnosed with confirmed relapsed or refractory haematological malignancies such as NHL, MM, or AML
- Previously received standard therapy for their condition
- Have adequate organ function
You will not qualify if you...
- Received chemotherapy, investigational agents, or other anti-cancer drugs within 14 days or 5 half-lives before starting study treatment
- Had a major surgery or significant injury within 4 weeks before study treatment
- Taken strong CYP3A4 inhibitors, CYP3A4 substrates with narrow therapeutic range, or CYP2C8 substrates with narrow therapeutic range within 2 weeks before starting study treatment
- Taken strong CYP3A4 inducers within 4 weeks before study treatment
- Currently taking statins (must discontinue before starting study treatment)
- Have unresolved toxicities from prior therapy greater than CTCAE grade 1 (except alopecia and grade 2 neuropathy) at the start of study treatment
- Have severe or uncontrolled systemic diseases
- Have any known uncontrolled inter-current illness
- Have QTcF prolongation greater than 470 msec
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 39 locations
1
Emory Winship Cancer Institute
Atlanta, Georgia, United States, 30322
Actively Recruiting
2
Community Health Network
Indianapolis, Indiana, United States, 46227
Actively Recruiting
3
The Center for Cancer and Blood Disorders (CCBD)
Bethesda, Maryland, United States, 20817
Actively Recruiting
4
Nebraska Cancer Specialists
Omaha, Nebraska, United States, 68130
Actively Recruiting
5
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198-6846
Actively Recruiting
6
Penn Medicine - Abramson Cancer Center Perelman
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
7
Institute Bergonie
Bordeaux, France, 33076
Completed
8
Gustave Roussy
Villejuif, France, 94805
Completed
9
Hospital Germans Trias i Pujol/ ICO Badalona
Badalona, Spain, 08916
Actively Recruiting
10
University Hospital Vall D'Hebron
Barcelona, Spain, 08035
Completed
11
Hospital Clínic de Barcelona
Barcelona, Spain, 08036
Actively Recruiting
12
ICO L'Hospitalet (Instituto Catalán de Oncología)
Barcelona, Spain, 08908
Actively Recruiting
13
Hospital Universitario de La Princesa
Madrid, Spain, 28006
Actively Recruiting
14
Hospital Universitario Gregorio Marañón
Madrid, Spain, 28009
Actively Recruiting
15
Hospital Infanta Leonor
Madrid, Spain, 28031
Actively Recruiting
16
Hospital Universitario Ramón y Cajal
Madrid, Spain, 28034
Actively Recruiting
17
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Actively Recruiting
18
CIOCC Hospital Universitario HM Sanchinarro
Madrid, Spain, 28050
Completed
19
Universidad de Navarra
Pamplona, Spain, 31008
Actively Recruiting
20
Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana
Valencia, Spain, 46026
Actively Recruiting
21
Karolinska Comprehensive Cancer Center
Stockholm, Sweden
Completed
22
The Royal Marsden
Sutton, Surrey, United Kingdom, SM2 5PT
Actively Recruiting
23
The Clatterbridge Cancer Centre NHS Foundation Trust,
Bebington, United Kingdom, CH63 4JY
Actively Recruiting
24
University Hospitals Bristol
Bristol, United Kingdom
Actively Recruiting
25
University Hospital of Wales
Cardiff, United Kingdom
Actively Recruiting
26
Royal Derby Hospital
Derby, United Kingdom, DE22 3NE
Actively Recruiting
27
Western General Hospital
Edinburgh, United Kingdom, EH4 2XU
Actively Recruiting
28
Gartnavel General Hospital
Glasgow, United Kingdom, G12 0YN
Actively Recruiting
29
Leicester Royal Infirmary
Leicester, United Kingdom
Actively Recruiting
30
St Bartholomew's Hospital
London, United Kingdom, EC1A 7BE
Actively Recruiting
31
Sarah Cannon Research Institute UK
London, United Kingdom, W1G 6AD
Actively Recruiting
32
NIHR University College London Clinical Research Facility
London, United Kingdom, W1T 7HA
Actively Recruiting
33
Imperial College
London, United Kingdom
Actively Recruiting
34
The Christie Hospital
Manchester, United Kingdom
Actively Recruiting
35
Newcastle upon Tyne Hospitals
Newcastle upon Tyne, United Kingdom
Actively Recruiting
36
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom, NG5 1PB
Actively Recruiting
37
Cancer and Haematology Centre
Oxford, United Kingdom, OX3 7LE
Actively Recruiting
38
University Hospital of Southampton
Southampton, United Kingdom, SO16 6YD
Actively Recruiting
39
Royal Stoke University Hospital
Stoke-on-Trent, United Kingdom, ST4 6QG
Actively Recruiting
Research Team
T
Tomasz Knurowski, PhD
CONTACT
K
Karen Clegg, MD, MFPM
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here